$71.28
0.68% today
Nasdaq, Aug 22, 10:01 pm CET
ISIN
US03940C1009
Symbol
ACLX

Arcellx Stock price

$71.28
+3.03 4.44% 1M
+8.27 13.12% 6M
-5.41 7.05% YTD
+4.82 7.25% 1Y
+53.15 293.16% 3Y
+56.28 375.20% 5Y
+56.28 375.20% 10Y
+56.28 375.20% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
-0.49 0.68%
ISIN
US03940C1009
Symbol
ACLX
Industry

Key metrics

Basic
Market capitalization
$4.0b
Enterprise Value
$3.5b
Net debt
positive
Cash
$453.1m
Shares outstanding
55.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
69.9 | 56.4
EV/Sales
61.9 | 49.9
EV/FCF
negative
P/B
10.2
Financial Health
Equity Ratio
63.9%
Return on Equity
-23.6%
ROCE
-43.1%
ROIC
-206.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$57.0m | $70.6m
EBITDA
$-208.1m | $-241.1m
EBIT
$-214.4m | $-247.3m
Net Income
$-188.0m | $-230.3m
Free Cash Flow
$-123.2m
Growth (TTM | estimate)
Revenue
-60.6% | -34.6%
EBITDA
-168.6% | -82.2%
EBIT
-165.8% | -79.8%
Net Income
-248.8% | -114.5%
Free Cash Flow
-187.5%
Margin (TTM | estimate)
Gross
-
EBITDA
-365.2% | -341.5%
EBIT
-376.3%
Net
-329.9% | -326.1%
Free Cash Flow
-216.3%
More
EPS
$-3.3
FCF per Share
$-2.2
Short interest
16.1%
Employees
163
Rev per Employee
$660.0k
Show more

Is Arcellx a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Arcellx Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Arcellx forecast:

24x Buy
96%
1x Hold
4%

Analyst Opinions

25 Analysts have issued a Arcellx forecast:

Buy
96%
Hold
4%

Financial data from Arcellx

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
57 57
61% 61%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 99 99
25% 25%
174%
- Research and Development Expense 172 172
18% 18%
302%
-208 -208
169% 169%
-365%
- Depreciation and Amortization 6.32 6.32
97% 97%
11%
EBIT (Operating Income) EBIT -214 -214
166% 166%
-376%
Net Profit -188 -188
249% 249%
-330%

In millions USD.

Don't miss a Thing! We will send you all news about Arcellx directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcellx Stock News

Positive
Seeking Alpha
15 days ago
We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divestiture of non-core assets, new leadership, and a focus on high-growth hospital monitoring technologies. Eli Lilly remains a core holding due to its leadership in diabetes and obesity treatments, robu...
Neutral
The Motley Fool
15 days ago
Arcellx (ACLX) Q2 Revenue Drops 72%
Neutral
Business Wire
15 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the second quarter ended June 30, 2025. “The data presented for all 117 patients enrolled in the registration...
More Arcellx News

Company Profile

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Rami Elghandour
Employees 163
Founded 2014
Website www.arcellx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today